What the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.35%Below 5Y avg (1.01%)
Annual Rate
CNY 0.05Paid unknown
Payout Ratio
0.0%Sustainable
Last Ex-Dividend
Aug 24, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
7.76BCNY
1.16B · vs all stocks (USD)
Updated Oct 21, 2026
Trailing P/E
60.04x
vs Biotechnology peers
Updated Oct 21, 2026
Revenue (TTM)
1.56BCNY
233.61M · vs all stocks (USD)
Updated Oct 21, 2026
Profit Margin
8.27%
vs Biotechnology peers
Updated Oct 21, 2026
Beta
0.2700x
vs all stocks
Updated Oct 21, 2026
52-Week Change
40.10%
vs all stocks
Updated Oct 21, 2026
Forward Annual Dividend Yield
0.35%
vs all stocks
Updated Oct 21, 2026
Market Capitalization
7.76BCNY
1.16B · vs all stocks (USD)
Updated Oct 21, 2026
Enterprise Value
8.90BCNY
1.33B · vs all stocks (USD)
Updated Oct 21, 2026
Trailing P/E
60.04x
vs Biotechnology peers
Updated Oct 21, 2026
Forward P/E
53.37x
vs Biotechnology peers
Updated Oct 21, 2026
Price to Sales (TTM)
4.98x
vs Biotechnology peers
Updated Oct 21, 2026
Price to Book (MRQ)
3.28x
vs Biotechnology peers
Updated Oct 21, 2026
Enterprise to Revenue
5.71x
vs Biotechnology peers
Updated Oct 21, 2026
Enterprise to EBITDA
25.79x
vs Biotechnology peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 48.55×.Updated Oct 21, 2026
Gross Margin
39.80%
vs Biotechnology peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 28.26%.Updated Oct 21, 2026
Profit Margin
8.27%
vs Biotechnology peers
Updated Oct 21, 2026
Operating Margin
24.08%
vs Biotechnology peers
Updated Oct 21, 2026
Return on Assets (TTM)
2.09%
vs Biotechnology peers
Updated Oct 21, 2026
Return on Equity (TTM)
5.20%
vs Biotechnology peers
Updated Oct 21, 2026
Revenue (TTM)
1.56BCNY
233.61M · vs all stocks (USD)
Updated Oct 21, 2026
Revenue per Share (TTM)
3.30CNYUpdated Oct 21, 2026
Quarterly Revenue Growth
88.80%
vs Biotechnology peers
Updated Oct 21, 2026
Gross Profit (TTM)
440.51MCNY
66.03M · vs all stocks (USD)
Updated Oct 21, 2026
EBITDA (TTM)
183.39MCNY
27.49M · vs all stocks (USD)
Updated Oct 21, 2026
Net Income (TTM)
128.83MCNY
19.31M · vs all stocks (USD)
Updated Oct 21, 2026
Quarterly Earnings Growth (YoY)
127.00%
vs Biotechnology peers
Updated Oct 21, 2026
Operating Cash Flow (TTM)
121.31MCNY
18.18M · vs all stocks (USD)
Updated Oct 21, 2026
Levered Free Cash Flow (TTM)
-103.44MCNY
-15.50M · vs all stocks (USD)
Updated Oct 21, 2026
Forward Annual Dividend Rate
0.0500CNYUpdated Oct 21, 2026
Forward Annual Dividend Yield
0.35%
vs all stocks
Updated Oct 21, 2026
Trailing Annual Dividend Rate
0.0500CNYUpdated Oct 21, 2026
Trailing Annual Dividend Yield
0.35%
vs all stocks
Updated Oct 21, 2026
5-Year Average Dividend Yield
1.01%
vs all stocks
Updated Oct 21, 2026
Payout Ratio
0.00%
vs Biotechnology peers
Provider-reported. Trailing Annual Dividend Rate ÷ Diluted EPS (TTM) on this page gives 20.83%.Updated Oct 21, 2026
Minority Interest (Equity)
16.38MCNYFY2025 · Dec 31, 2025
Revenue
1.18BCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
986.85MCNYFY2025 · Dec 31, 2025
Gross Profit
198.14MCNYFY2025 · Dec 31, 2025
Operating Income
8.57MCNY
1.28M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-65.21MCNYFY2025 · Dec 31, 2025
Income Tax Expense
-2.24MCNYFY2025 · Dec 31, 2025
Net Income
-62.97MCNYFY2025 · Dec 31, 2025
EBIT
-18.97MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
183.39MCNYFY2025 · Dec 31, 2025
Research & Development
59.50MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
62.78MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
17.43MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
5.51MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
46.24MCNYFY2025 · Dec 31, 2025
EPS (Basic)
-0.1000CNYFY2025 · Dec 31, 2025
EPS (Diluted)
-0.1000CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
550.26MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
550.26MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-62.97MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
7.94MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
-2.10MCNYFY2025 · Dec 31, 2025
Free Cash Flow
-226.24MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
464.07MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-62.97MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
46.41MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
-16.76MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
31.22MCNYFY2025 · Dec 31, 2025
Capital Expenditures
-224.14MCNYFY2025 · Dec 31, 2025
Purchase of Investments
-170.00MCNYFY2025 · Dec 31, 2025
Sale of Investments
174.26MCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
-219.88MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
950.00MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-903.78MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-54.77MCNYFY2025 · Dec 31, 2025
Other Financing Charges
81.16MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
72.62MCNYFY2025 · Dec 31, 2025
Shares Outstanding
538.65MSharesUpdated Oct 21, 2026
Float Shares
413.04MSharesUpdated Oct 21, 2026
% Held by Insiders
27.37%
vs all stocks
Updated Oct 21, 2026
% Held by Institutions
0.51%
vs all stocks
Updated Oct 21, 2026
Total Cash (MRQ)
492.40MCNY
73.81M · vs all stocks (USD)
Updated Oct 21, 2026
Total Cash per Share (MRQ)
0.9140CNYUpdated Oct 21, 2026
Total Debt (MRQ)
1.60BCNY
239.69M · vs all stocks (USD)
Updated Oct 21, 2026
Total Debt to Equity (MRQ)
0.6711x
vs Biotechnology peers
Updated Oct 21, 2026
Current Ratio (MRQ)
1.28x
vs Biotechnology peers
Updated Oct 21, 2026
Book Value per Share (MRQ)
4.39CNYUpdated Oct 21, 2026
Total Assets
4.40BCNY
660.23M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
1.46BCNYFY2025 · Dec 31, 2025
Total Liabilities
2.20BCNYFY2025 · Dec 31, 2025
Total Non-current Assets
2.94BCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
935.30MCNYFY2025 · Dec 31, 2025
Total Current Liabilities
1.27BCNYFY2025 · Dec 31, 2025
Cash
464.54MCNYFY2025 · Dec 31, 2025
Cash Equivalents
18.44MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
482.98MCNYFY2025 · Dec 31, 2025
Other Short-term Investments
954.50KCNYFY2025 · Dec 31, 2025
Accounts Receivable
370.25MCNYFY2025 · Dec 31, 2025
Inventory
379.93MCNYFY2025 · Dec 31, 2025
Accounts Payable
348.04MCNYFY2025 · Dec 31, 2025
Short-term Debt
841.52MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
39.21MCNYFY2025 · Dec 31, 2025
Long-term Debt
809.46MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
538.65MCNYFY2025 · Dec 31, 2025
Retained Earnings
209.49MCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
2.20BCNY
329.79M · vs all stocks (USD)
FY2025 · Dec 31, 2025
52-Week Low
9.72CNYUpdated Oct 21, 2026
52-Week High
24.18CNYUpdated Oct 21, 2026
52-Week Change
40.10%
vs all stocks
Updated Oct 21, 2026
Beta
0.2700x
vs all stocks
Updated Oct 21, 2026
50-Day MA
18.25CNYUpdated Oct 21, 2026
200-Day MA
17.58CNYUpdated Oct 21, 2026
Avg 10-Day Volume
40.76MSharesUpdated Oct 21, 2026
Avg 30-Day Volume
40.27MSharesUpdated Oct 21, 2026
Diluted EPS (TTM)
0.2400CNYUpdated Oct 21, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 2.49: grey zoneSignificant
Altman Z-Score: 2.49
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.16B, above the global median of $1.14BNotable
Market cap (USD): 1,163,435,858.275Global Median: 1,137,180,293.291
Companies that share the same coordination system — how they create, deliver, or capture value.